Skip to main content

Invivo Therapeutics Holdings Corp. (NVIV)

NASDAQ: NVIV · IEX Real-Time Price · USD
0.601
-0.001 (-0.20%)
After-hours:Oct 22, 2021 6:44 PM EDT
0.602
-0.026 (-4.09%)
At close: Oct 22, 4:00 PM
Market Cap20.62M
Revenue (ttm)n/a
Net Income (ttm)-9.00M
Shares Out34.26M
EPS (ttm)-0.42
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume686,075
Open0.620
Previous Close0.628
Day's Range0.601 - 0.620
52-Week Range0.498 - 2.000
Beta1.27
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 4, 2021

About NVIV

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). The company is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusett...

IndustryHealth Care Equipment & Supplies
CEORichard Toselli
Employees6
Stock ExchangeNASDAQ
Ticker SymbolNVIV
Full Company Profile

Financial Performance

Financial Statements

News

7 Biotech Stocks to Buy That Have Millionaire-Maker Potential

This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.

Other symbols:AVIRHSTONRBOPRVBSYN
1 month ago - InvestorPlace

InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord in...

1 month ago - Business Wire

InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord in...

1 month ago - Business Wire

3 Biotech Penny Stocks That You Need to Know About In 2021

Are these the best biotech penny stocks to watch in 2021? The post 3 Biotech Penny Stocks That You Need to Know About In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt...

Other symbols:NRBOSYN
3 months ago - PennyStocks

Best Penny Stocks To Watch For July 2021

Penny Stocks For Your Watch List In July The post Best Penny Stocks To Watch For July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:AHTBTB
3 months ago - PennyStocks

InVivo Therapeutics Stock Moves Higher On FDA Acceptance Of Preclinical Module For Neuro-Spinal Implant

The FDA has accepted InVivo Therapeutics Holdings Corp's (NASDAQ: NVIV) preclinical module, which is one of three individual modules required for the Company's humanitarian device exemption (HDE) applic...

3 months ago - Benzinga

InVivo Therapeutics Announces FDA Acceptance of Preclinical Module in Support of Company's Complete HDE Submission

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord in...

3 months ago - Business Wire

InVivo Therapeutics Urges All Stockholders to Vote at the 2021 Annual Meeting to Be Held on Friday July 16, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord in...

3 months ago - Business Wire

InVivo Therapeutics Announces Presentation at Upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtu...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord in...

7 months ago - Business Wire

InVivo Therapeutics Announces Presentation at Upcoming 2021 H.C. Wainwright Global Life Sciences Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord in...

7 months ago - Business Wire

InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the recent publication of a peer-reviewed manuscript in the Journal of Neurosurgery: Spine describing...

8 months ago - Business Wire

InVivo Therapeutics Announces Closing of $15.0 Million Public Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its previously announced public offering of 18,750,000 shares of its common stock (or ...

11 months ago - Business Wire

InVivo Therapeutics Announces Presentation at the Upcoming H.C Wainwright Virtual Global Investment Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp.

1 year ago - Business Wire